BR0009646A - Terapia de melanoma - Google Patents

Terapia de melanoma

Info

Publication number
BR0009646A
BR0009646A BR0009646-6A BR0009646A BR0009646A BR 0009646 A BR0009646 A BR 0009646A BR 0009646 A BR0009646 A BR 0009646A BR 0009646 A BR0009646 A BR 0009646A
Authority
BR
Brazil
Prior art keywords
melanoma
alpha
therapy
treatment
melanoma therapy
Prior art date
Application number
BR0009646-6A
Other languages
English (en)
Inventor
Mary Ellen Rybak
Esther Helen Rose
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of BR0009646A publication Critical patent/BR0009646A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Patente de Invenção: "TERAPIA DE MELANOMA". A invenção refere-se a métodos para tratar pacientes não submetidos a tratamento, bem como experimentados com tratamento que apresentam melanoma para aumentar o tempo de sobrevivência sem progressão que envolve administrar uma quantidade terapeuticamente eficaz de interferon-alfa pegilado, por exemplo, preferencialmente interferon alfa-2b pegilado, como terapia adjuvante para cirurgia definitiva.
BR0009646-6A 1999-04-08 2000-04-06 Terapia de melanoma BR0009646A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28836699A 1999-04-08 1999-04-08
PCT/US2000/009129 WO2000061175A2 (en) 1999-04-08 2000-04-06 Use of pegylated interferon alpha in melanoma therapy

Publications (1)

Publication Number Publication Date
BR0009646A true BR0009646A (pt) 2002-02-05

Family

ID=23106795

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0009646-6A BR0009646A (pt) 1999-04-08 2000-04-06 Terapia de melanoma

Country Status (22)

Country Link
EP (3) EP2025344B1 (pt)
JP (1) JP2000319195A (pt)
CN (1) CN1390132A (pt)
AR (1) AR023398A1 (pt)
AT (3) ATE296639T1 (pt)
AU (1) AU771569B2 (pt)
BR (1) BR0009646A (pt)
CA (1) CA2303992A1 (pt)
CO (1) CO5170404A1 (pt)
CY (1) CY1108922T1 (pt)
DE (3) DE60020444T2 (pt)
DK (2) DK1535622T3 (pt)
ES (2) ES2319776T3 (pt)
HK (2) HK1032349A1 (pt)
HU (1) HU230057B1 (pt)
MY (1) MY126763A (pt)
NO (1) NO328111B1 (pt)
PE (1) PE20010027A1 (pt)
PT (2) PT1535622E (pt)
TW (1) TWI292320B (pt)
WO (1) WO2000061175A2 (pt)
ZA (1) ZA200108173B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9107887B2 (en) 2011-03-10 2015-08-18 Provectus Pharmaceuticals, Inc. Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4492537A (en) 1982-12-10 1985-01-08 Awerkamp John B Fluid-operated oil or water well pump
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
NZ276943A (en) 1993-11-10 1998-02-26 Schering Corp Substituted For Alpha-interferon conjugated to a non-antigenic polymer (preferably a polyalkylene oxide) and its preparation
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
JP2758154B2 (ja) 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates

Also Published As

Publication number Publication date
PT1043026E (pt) 2005-09-30
AU4204600A (en) 2000-11-14
DE60045591D1 (de) 2011-03-10
ES2319776T3 (es) 2009-05-12
EP1043026A2 (en) 2000-10-11
EP1043026B1 (en) 2005-06-01
PE20010027A1 (es) 2001-02-05
HK1032349A1 (en) 2001-07-20
NO20014852D0 (no) 2001-10-05
CN1390132A (zh) 2003-01-08
ATE419001T1 (de) 2009-01-15
EP2025344A1 (en) 2009-02-18
CO5170404A1 (es) 2002-06-27
EP1535622B1 (en) 2008-12-31
PT1535622E (pt) 2009-03-19
NO20014852L (no) 2001-12-06
NO328111B1 (no) 2009-12-07
DK1535622T3 (da) 2009-04-20
WO2000061175A2 (en) 2000-10-19
JP2000319195A (ja) 2000-11-21
EP2025344B1 (en) 2011-01-26
HK1075416A1 (en) 2005-12-16
AR023398A1 (es) 2002-09-04
HU230057B1 (hu) 2015-06-29
TWI292320B (en) 2008-01-11
ES2239954T3 (es) 2005-10-16
DE60020444D1 (de) 2005-07-07
MY126763A (en) 2006-10-31
DE60041290D1 (de) 2009-02-12
AU771569B2 (en) 2004-03-25
EP1043026A3 (en) 2000-12-20
WO2000061175A3 (en) 2001-02-01
CY1108922T1 (el) 2014-07-02
HUP0200775A2 (en) 2002-08-28
ZA200108173B (en) 2003-01-06
EP1535622A1 (en) 2005-06-01
DE60020444T2 (de) 2006-05-04
ATE496631T1 (de) 2011-02-15
HUP0200775A3 (en) 2002-09-30
DK1043026T3 (da) 2005-07-04
ATE296639T1 (de) 2005-06-15
CA2303992A1 (en) 2000-10-08

Similar Documents

Publication Publication Date Title
IL256054A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
CY1118849T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
TW265265B (pt)
BR9911076A (pt) Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica
BR9913319A (pt) Composições e métodos para tratamento de doenças mitocondriais
BR9809425A (pt) Conjugados alfa interferon-polietilenoglicol para terapia de infecção
DK1137762T3 (da) Behandling af Pompes sygdom
ATE450269T1 (de) Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
HUP0002755A2 (hu) Eljárások szklerózis multiplexben szenvedő betegek kezelésére konszenzus interferonnal
WO2005063297A3 (en) Melatonin combination therapy for improving sleep quality
ES2177780T3 (es) Medicamentos para el tratamiento de enfermedades autoinmunes usando interferon tau.
KR960702318A (ko) 근육 질병 및 장애의 치료방법
RS20050344A (en) Treatment for hemorrhagic shock
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
FR2721516B1 (fr) Nouvelles utilisations d'un complexe à base de phospholipides cérébraux en thérapeutique et dans l'alimentation.
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
AP1896A (en) The method of treating cancer
BR0009646A (pt) Terapia de melanoma
IL159770A0 (en) Calcium salts with cytotoxic activity
BR0009642A (pt) Terapia de leucemia mielocìtica crÈnica
ECSP003419A (es) Terapia para melanomas
BR9812466A (pt) Uso de ifn-alfa e amantadina para o tratamento da hepatite c crÈnica
WO2003059334A3 (en) Gemcitabine in the treatment of smallpox
TW200519078A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture
MX9704887A (es) Composiciones farmaceuticas para el tratamiento de trastornos depresivos.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 10 E 37 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.

B25E Requested change of name of applicant rejected

Owner name: SCHERING CORPORATION (US)

Free format text: INDEFERIDO O PEDIDO DE ALTERACAO DE NOME CONTIDO NA PETICAO 020130028696 DE 05/04/2013, CONFORME DISPOSTO NO ART. 59 DA LEI 9279 DE 14/05/1996, PELO FATO DO PEDIDO DE PATENTE TER SIDO INDEFERIDO NA RPI 2251 DE 25/02/2014.

Owner name: SCHERING CORPORATION (US)

B25H Request for change of headquarter rejected

Owner name: SCHERING CORPORATION (US)